Search Results

The first East Coast installation of the MOMENTUM Magnetic Particle Imaging (MPI) scanner has been completed at Kennedy Krieger Institute in Baltimore, MD.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the start of a preclinical collaboration on Kabuki Syndrome with researchers from Kennedy Krieger Institute and Johns Hopkins University.

Carisma Therapeutics Inc. today announced the appointment of Eugene P. Kennedy, M.D., F.A.C.S. as the Company’s Chief Medical Officer.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of a new independent director, Patrick Kennedy, to its Board of Directors.

Daré Bioscience, Inc. today announced that it received a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the National Institutes of Health (NIH).

Avenue Therapeutics, Inc. today announced the completion of the last patient’s final visit in the Company’s Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar muscular atrophy (“SBMA”), also known as Kennedy’s Disease.

Nido Biosciences announced positive results from its Phase 1 study of NIDO-361 in healthy male subjects and interim results from its observational study at the 2023 International Kennedy’s Disease Patient Conference in London, November 4 – 5.

Kennedy Krieger Institute, internationally known for providing a wide range of services for children, adolescents and adults with diseases, disorders or injuries that impact the nervous system, recently received a grant of $994,950 from the Federal Communications Commission to expand and improve access to its telehealth services.